Myeloproliferative Disorders: all 640 studies

Page 2 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
• Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingNCT03589729Phase 2
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
• Project: Every Child for Younger Patients With CancerRecruitingNCT02402244
• Registry of Philadelphia-Negative Myeloproliferative NeoplasmsRecruitingNCT02380378
• Pathogenesis of Hematologic MalignanciesEnrolling by invitationNCT01728402
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
• Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)CompletedNCT05177211Phase 2Results posted
• PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
• Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsTerminatedNCT05005182Phase 2Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3Results posted
• ADCT-301 in Patients With R/R AML, MDS, or MDS/MPNTerminatedNCT04639024Phase 2Results posted
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to ApplyCompletedNCT04182100Phase 2Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN PatientsTerminatedNCT04103645Phase 2Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IICompletedNCT03941769Phase 1/2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionCompletedNCT03480360Phase 3Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNActive, not recruitingNCT03386513Phase 1/2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsCompletedNCT03238248Phase 2Results posted
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
• Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)CompletedNCT03149055Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)CompletedNCT03140280Phase 2Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative NeoplasmsCompletedNCT03075826Phase 2Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)CompletedNCT03011372Phase 2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingNCT02521493Phase 3Results posted
• Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantActive, not recruitingNCT02506933Phase 2Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or LymphomaCompletedNCT02424968Phase 2Results posted
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)TerminatedNCT02410551Phase 2Results posted
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT02396134Phase 2Results posted
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted
• Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet DepletionsCompletedNCT02308787Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownNCT01894477Phase 2Results posted
• Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide GeneTerminatedNCT01875237Phase 1/2Results posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Preventing Stem Cell Transplant Complications With a Blood Separator MachineCompletedNCT01866839Phase 1/2Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaCompletedNCT01712308Phase 2Results posted
• HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETTerminatedNCT01668173Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)TerminatedNCT01518153Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01444742Phase 2Results posted
• Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFCompletedNCT01423851Phase 1/2Results posted
• Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative DisordersCompletedNCT01392989Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Preservation of Ovarian Function After Hematopoietic Cell TransplantTerminatedNCT01343368Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 3Results posted
• Study of SB939 in Subjects With MyelofibrosisCompletedNCT01200498Phase 2Results posted
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted

← Myeloproliferative Disorders overview